Has Andres Riera, MD received payments from drug or device companies?

Yes. Drug and device makers reported $237,389 in general payments to Andres Riera, MD across 369 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andres Riera, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andres Riera, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andres Riera, MD

Internal Medicine · Reading, PANPI 1841569167

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $191,651 of the $237,389 with a category attached, or 80.7%. 10 manufacturers reported payments, led by AbbVie at 32.4% of the total. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$237,389in general payments, 2019–2025

Across 369 payments — averaging $643.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$77K
AstraZeneca$72K
Madrigal Pharmaceuticals$44K
Novo Nordisk$36K
Gilead$8K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$436
plus $216 from 4 others

$35,415in research payments, 2019–2025

Across 12 payments — averaging $2951.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Intercept Pharmaceuticals, Inc.$18K
Mallinckrodt Enterprises LLC$8K
Intercept Pharma Europe Ltd.$7K
AstraZeneca$3K

What the payments were for

Consulting fees$16,4357%
Speaking & faculty fees$191,65181%
Travel & lodging$20,2359%
Food & beverage$8,9724%
Education$970%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	119	$76,887
AstraZeneca	123	$71,949
Madrigal Pharmaceuticals	47	$43,939
Novo Nordisk	28	$36,180
Gilead	26	$7,783
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	20	$436
Mallinckrodt Hospital Products Inc.	2	$136
Intercept Pharmaceuticals, Inc.	2	$35
Takeda Pharmaceuticals U.S.A., Inc.	1	$28
Dova Pharmaceuticals	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Mavyret$74,340
REZDIFFRA$42,710
Wegovy$31,291
Kanuma$5,561
Vemlidy$3,195
RESMETIROM$126
Strensiq$124

How this compares

$237,389 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$44,249

Medicare patients

183

Services billed

250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RezdiffraResmetirom	19	$84,651
XifaxanRifaximin	12	$55,612
Tacrolimus	199	$45,307
OzempicSemaglutide	23	$21,782
VemlidyTenofovir Alafenamide	11	$18,106
Ursodiol	55	$10,270
Lamivudine HbvLamivudine	31	$9,443
Sirolimus	13	$8,190
Mycophenolate Mofetil	43	$2,538
Azathioprine	41	$1,760
Prednisone	50	$328
Pantoprazole Sodium	17	$258
Spironolactone	29	$248
Omeprazole	16	$240
Lactulose	11	$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Madrigal PharmaceuticalsRezdiffra	$43,939	$84,65119 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan	$436	$55,61212 claims
Novo NordiskOzempic	$36,180	$21,78223 claims
GileadVemlidy	$7,783	$18,10611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.